12 Month Price Forecast For NBIX
Distance to NBIX Price Forecasts
NBIX Price Momentum
🤔 Considering Neurocrine (NBIX)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 11, 2025 4:21 AM UTC
NBIX Analyst Ratings & Price Targets
Based on our analysis of 33 Wall Street analysts, NBIX has a bullish consensus with a median price target of $168.00 (ranging from $140.00 to $192.00). The overall analyst rating is Strong Buy (8.9/10). Currently trading at $118.81, the median forecast implies a 41.4% upside. This outlook is supported by 21 Buy, 4 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Uy Ear at Mizuho, suggesting a 17.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NBIX Analyst Consensus
NBIX Price Target Range
Latest NBIX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NBIX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 10, 2025 | Guggenheim | Yatin Suneja | Buy | Maintains | $163.00 |
| Feb 10, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $185.00 |
| Feb 7, 2025 | HC Wainwright & Co. | Andrew Fein | Buy | Maintains | $185.00 |
| Feb 7, 2025 | B of A Securities | Tazeen Ahmad | Buy | Maintains | $179.00 |
| Feb 7, 2025 | Needham | Ami Fadia | Hold | Reiterates | $0.00 |
| Feb 7, 2025 | Wedbush | Laura Chico | Outperform | Maintains | $147.00 |
| Feb 7, 2025 | RBC Capital | Brian Abrahams | Sector Perform | Maintains | $148.00 |
| Feb 7, 2025 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $163.00 |
| Feb 4, 2025 | Morgan Stanley | Jeffrey Hung | Overweight | Maintains | $185.00 |
| Jan 30, 2025 | UBS | Ashwani Verma | Buy | Maintains | $176.00 |
| Jan 8, 2025 | UBS | Ashwani Verma | Buy | Maintains | $162.00 |
| Dec 23, 2024 | Piper Sandler | David Amsellem | Overweight | Reiterates | $160.00 |
| Dec 23, 2024 | Barclays | Carter Gould | Overweight | Maintains | $165.00 |
| Dec 20, 2024 | Needham | Ami Fadia | Hold | Reiterates | $0.00 |
| Dec 16, 2024 | Wedbush | Laura Chico | Outperform | Reiterates | $148.00 |
| Dec 16, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $190.00 |
| Nov 11, 2024 | Needham | Ami Fadia | Hold | Reiterates | $0.00 |
| Nov 1, 2024 | HC Wainwright & Co. | Andrew Fein | Buy | Reiterates | $190.00 |
| Oct 31, 2024 | Needham | Ami Fadia | Hold | Reiterates | $0.00 |
| Oct 30, 2024 | Needham | Ami Fadia | Hold | Reiterates | $0.00 |
Stocks Similar to Neurocrine Biosciences Inc
The following stocks are similar to Neurocrine based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Neurocrine Biosciences Inc (NBIX) Financial Data
Neurocrine Biosciences Inc has a market capitalization of $11.88B with a P/E ratio of 35.7x. The company generates $2.24B in trailing twelve-month revenue with a 17.2% profit margin.
Revenue growth is +24.7% quarter-over-quarter, while maintaining an operating margin of +29.7% and return on equity of +16.3%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Neurocrine Biosciences Inc (NBIX) Company Overview
About Neurocrine Biosciences Inc
Develops pharmaceuticals for neurological disorders.
Neurocrine Biosciences generates revenue through the discovery, development, and marketing of innovative pharmaceutical products targeting neurological, neuroendocrine, and neuropsychiatric disorders. The company markets several approved products while also advancing a robust pipeline of candidates in clinical development, aiming to address various conditions such as dyskinetic cerebral palsy and major depressive disorder.
Neurocrine has established multiple collaboration agreements with major pharmaceutical companies, enhancing its research capabilities and market reach. Founded in 1992 and based in San Diego, California, the company has a strong focus on addressing unmet medical needs in the CNS space, making it an attractive option for investors interested in the biotech sector.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
1,700
CEO
Mr. Kyle W. Gano Ph.D.
Country
United States
IPO Year
1996
Website
www.neurocrine.comNeurocrine Biosciences Inc (NBIX) Latest News & Analysis
Neurocrine Biosciences Reports Mixed Q4
4 days agoNeurocrine Biosciences reported mixed Q4 earnings: revenue slightly missed expectations, but adjusted EPS exceeded estimates.
Mixed earnings can signal volatility. A revenue miss could indicate potential challenges ahead, while strong EPS suggests operational efficiency, impacting stock performance and investor sentiment.
Neurocrine's stock declined after the company provided weak 2025 guidance for Ingrezza, its key drug.
Neurocrine's weak 2025 guidance for Ingrezza signals potential revenue declines, raising concerns about future growth and profitability, impacting investor sentiment and stock value.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will hold its Q4 2024 earnings call on February 6, 2025, at 4:30 PM ET, featuring key executives and analysts from various financial institutions.
The earnings call indicates upcoming financial performance insights for Neurocrine Biosciences, influencing stock valuation and investor sentiment based on growth potential and market strategies.
Neurocrine Biosciences reported Q4 2024 net sales of INGREZZA at $615M, with full-year sales of $2.3B, up 23%. 2025 guidance is $2.5-$2.6B. CRENESSITY launched; new studies for Osavampator and NBI-'568 starting in H1 2025.
Strong sales growth for INGREZZA and new product launches signal positive momentum for Neurocrine Biosciences, potentially boosting investor confidence and stock performance.
Neurocrine Biosciences Inc. (NBIX) reported Q4 adjusted EPS of $1.69, surpassing last year's $1.54 and exceeding the consensus estimate of $1.56.
Neurocrine Biosciences' Q4 EPS beat expectations, indicating strong financial performance and potential growth, which can boost investor confidence and stock value.
Neurocrine Biosciences (NBIX) reported quarterly earnings of $1 per share, below the Zacks Consensus Estimate of $1.56 and down from $1.44 per share a year earlier.
Neurocrine's earnings miss signals potential operational issues and may impact investor confidence, leading to stock price volatility and reassessment of growth prospects.
Frequently Asked Questions About NBIX Stock
What is Neurocrine Biosciences Inc's (NBIX) stock forecast for 2025?
Based on our analysis of 33 Wall Street analysts, Neurocrine Biosciences Inc (NBIX) has a median price target of $168.00. The highest price target is $192.00 and the lowest is $140.00.
Is NBIX stock a good investment in 2025?
According to current analyst ratings, NBIX has 21 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $118.81. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for NBIX stock?
Wall Street analysts predict NBIX stock could reach $168.00 in the next 12 months. This represents a 41.4% increase from the current price of $118.81. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Neurocrine Biosciences Inc's business model?
Neurocrine Biosciences generates revenue through the discovery, development, and marketing of innovative pharmaceutical products targeting neurological, neuroendocrine, and neuropsychiatric disorders. The company markets several approved products while also advancing a robust pipeline of candidates in clinical development, aiming to address various conditions such as dyskinetic cerebral palsy and major depressive disorder.
What is the highest forecasted price for NBIX Neurocrine Biosciences Inc?
The highest price target for NBIX is $192.00 from at , which represents a 61.6% increase from the current price of $118.81.
What is the lowest forecasted price for NBIX Neurocrine Biosciences Inc?
The lowest price target for NBIX is $140.00 from Uy Ear at Mizuho, which represents a 17.8% increase from the current price of $118.81.
What is the overall NBIX consensus from analysts for Neurocrine Biosciences Inc?
The overall analyst consensus for NBIX is bullish. Out of 33 Wall Street analysts, 21 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $168.00.
How accurate are NBIX stock price projections?
Stock price projections, including those for Neurocrine Biosciences Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
